FLUIFORT * 10BUST GRAT 2.7G
Mucolytic, fluidifying in acute and chronic respiratory diseases.
Dosage and method of use
1 sachet a day. In consideration of the pharmacokinetic characteristics, the recommended posology can be maintained even in patients with renal and hepatic insufficiency. Duration of treatment: carbocysteine lysine salt monohydrate can also be used for prolonged periods, in this case it is advisable to follow the doctor's advice. Instructions for using the sachet: dissolve the contents of the sachet in about half a glass of water, mixing well.
Hypersensitivity to the active substance or to any of the excipients. Gastroduodenal ulcer. Pregnancy and breastfeeding. The drug is contraindicated in patients of pediatric age (under 11 years).
Side effects that may occur with Fluifort, classified by system organ (SOC), are as follows: Skin, subcutaneous tissue disorders : skin rash, urticaria, erythema, rash, rash / erythema bullous, pruritus, angioedema, dermatitis. Gastrointestinal disorders : abdominal pain, nausea, vomiting, diarrhea. Nervous system disorders : dizziness. Respiratory, thoracic and mediastinal disorders : dyspnoea. Vascular pathologies: redness.
There are no known phenomena of addiction or dependence. Fluifort 2.7 g granules for oral solution does not affect low-calorie or controlled diets and can also be administered to diabetic patients. Fluifort 2.7 g granules for oral solution does not contain gluten; therefore it can be administered to patients with celiac disease. Fluifort 2.7 g granules for oral solution contains aspartame as a sweetener: this substance is contraindicated in subjects suffering from phenylketonuria. Dissolve the contents of the sachet in about half a glass of water, stirring well.
Pregnancy and breastfeeding
Although the active substance is neither teratogenic nor mutagenic and has not shown negative effects on reproductive function in animals, Fluifort should not be administered during pregnancy (see 4.3). As no data are available regarding the passage of carbocysteine lysine salt monohydrate into breast milk, use during lactation is contraindicated (see 4.3).
Expiration and retention
This medicine does not require any special storage conditions.
Interactions with other drugs
In controlled clinical trials, no interactions were found with the most common drugs used in the treatment of upper and lower respiratory tract diseases, nor with food and with laboratory tests.
Symptoms reported in case of overdose are: headache, nausea, vomiting, diarrhea, gastralgia, skin reactions, alteration of sensory systems. There is no specific antidote; it is advisable to induce vomiting and possibly perform gastric lavage followed by specific supportive therapy.
1 sachet of 5 g contains: active ingredient: carbocysteine lysine salt monohydrate equal to 2.7 g of carbocysteine lysine salt Excipients: aspartame For the full list of excipients, see section 6.1.
Citric acid, mannitol, povidone, natural cedar flavor, natural orange flavor, orange juice, aspartame, maltodextrin.